| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.001 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.19 | 0.001 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.13 | 0.002 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | 0.13 | 0.002 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.097 | 0.002 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |